PRE-I-SPY Phase I/Ib Oncology Platform Program
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
I-SPY Phase I/Ib (I-SPY-P1) is an open-label, multisite platform study designed to evaluate single agents or combinations in a metastatic treatment setting that may be relevant for breast cancer patients with the overall goal of moving promising drug regimens into the I-SPY 2 SMART Design Trial (NCT01042379) and/or other oncology-based trials in a timely manner.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Podpisana świadoma zgoda
- •Wiek od 18 lat
- •Dobry stan sprawności (ECOG 0-2)
- •Oczekiwane przeżycie >12 tygodni
- •Prawidłowa funkcja narządów (krew, wątroba, nerki)
- •Ujemny test ciążowy lub zgoda na antykoncepcję
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- April 4, 2025
- Sex
- No restrictions
Therapies / drugs in trial
Locations (7)
The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center
Birmingham, United States
Moffitt Cancer Center
Tampa, United States
The University of Chicago Medicine Comprehensive Cancer Center
Chicago, United States
UChicago Medicine Comprehensive Cancer Center at Silver Cross Hospital
New Lenox, United States
UChicago Medicine Orland Park
Orland Park, United States
University of Minnesota Masonic Cancer Center
Minneapolis, United States
The University of Texas MD Anderson Cancer Center
Houston, United States
Trial contact
Maria Pitsiouni, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.